Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers Meeting Abstract
| Authors: | Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; Ladanyi, M.; Hyman, D. M.; Sirulnik, L. A.; Drilon, A. |
| Abstract Title: | Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers |
| Meeting Title: | AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
| Journal Title: | Molecular Cancer Therapeutics |
| Volume: | 18 |
| Issue: | 12 Suppl. |
| Meeting Dates: | 2019 Oct 26-30 |
| Meeting Location: | Boston, MA |
| ISSN: | 1535-7163 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-12-01 |
| Language: | English |
| ACCESSION: | WOS:000510047200443 |
| DOI: | 10.1158/1535-7163.Targ-19-pr02 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: PR02 -- Source: Wos |
